Randel E. Richner has been appointed as Director of the Company effective 11/1/2020. She has over thirty years’ experience in health policy, reimbursement, and economics. From 2013 to 2015, Ms. Richner served as Executive Vice President of Intralign Health, LLC. From 2006 to 2012, she was President and Founder of Neocure Group, data analytics, health economics and reimbursement strategic services, acquired by Intralign Health, LLC, 2013. From 1997 to 2006, Ms. Richner was Vice President of Global Government Affairs and Reimbursement, Boston Scientific Corporation. Ms. Richner has engaged with U.S. Congress and CMS, appointed as first industry representative, Executive Committee (EC) Medicare Coverage Advisory Committee (MCAC). Presently, she is on the Executive Dean’s Advisory Board, University of Michigan’s School of Public Health, Executive Board MichBio, Chairperson, Diversity Council. Ms. Richner has served on multiple boards including MassMedic (founding Women in MedTech), Executive Advisory Board Center for Evaluation Value, Risk Tufts New England Medical Center, International Society of Pharmacoeconomics and Research (ISPOR), founding the U.S. Medical Device Council. She’s an invited executive lecturer Dartmouth, Tuck School of Business, University of Michigan School of Engineering and School of Public Health. She has a Master of Public Health in Health Policy and Administration and a Bachelor of Science in Nursing from University of Michigan.
Randel Richner is 65, she's been the Director of Rewalk Robotics Ltd since 2020. There are 2 older and 12 younger executives at Rewalk Robotics Ltd. The oldest executive at Rewalk Robotics Ltd is Ami Kraft, 78, who is the Exec. Advisor to the CEO.
Randel's mailing address filed with the SEC is C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., P.O. BOX 161, YOKNEAM ILIT, L3, 20692203.
Over the last 9 years, insiders at Rewalk Robotics Ltd have traded over $7,660,045 worth of Rewalk Robotics Ltd stock and bought 8,170,475 units worth $6,701,652 . The most active insiders traders include Global Fund Ii Lp Lind Glob..., Glenn P Muir, and Wayne Weisman. On average, Rewalk Robotics Ltd executives and independent directors trade stock every 26 days with the average trade being worth of $88,081. The most recent stock trade was executed by Global Fund Ii Lp Lind on 17 November 2023, trading 54,917 units of RWLK stock currently worth $40,089.
exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the
Rewalk Robotics Ltd executives and other stock owners filed with the SEC include: